Exelixis | EXEL - Gastos De Venta Y Administración

Precio De Mercado
44.27
Cambio Diario
-1.14 -2.51%
Mensual
6.04%
Anual
25.38%
Q2 Expectativa
43.06




Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Bayer EUR 4.05B 647M 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Cytokinetics USD 91.72M 67.02M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 123.02M 19.9M 2025-12
Genmab DKK 208M 60M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
Pfizer USD 4.08B 894M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sanofi EUR 2.75B 455M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Xencor USD 17.04M 70.74M 2025-12